Novartis has been ranked as the No. 1 company worldwide in the pharmaceuticals industry in the latest peer group results of the annual Fortune magazine survey of the “World’s Most Admired Companies.”
Opposition to current drug safety legislation is growing, as a group of 22 experts on drug safety and regulation and a coalition of 12 patient, consumer, science, and public health organizations issue two separate open letters to lawmakers.
High-temperature superconductors hold the key to a handheld tool for surgeons that promises to be more accurate, cost-effective and safer than existing methods for staging and treating various cancers, including breast cancer.
“Nanotechnology has the potential to generate enormous health benefits for the more than five billion people living in the developing world,” according to Dr. Peter A. Singer, senior scientist at the McLaughlin-Rotman Centre for Global Health and Professor of Medicine at University of Toronto.
On the second day of the National Governors Association (NGA) Winter Meeting, governors focused on the importance of science, technology, engineering and math (STEM) education in creating a competitive global economy.
Stem cells are capable of developing into any other type of cell. Researchers have now detected a gene-family that is essential for regulating the differentiation potential and growth of stem cells.
Eli Lilly and Company announced the launch of the first insulin pen with memory, HumaPen(R) MEMOIR(TM), to help simplify the daily management of diabetes.
The Office of Fair Trading (OFT) market study has today recommended a fundamental reform of the drug pricing system in the UK, which would see the current profit and price controls replaced with a value-based approach to pricing.
The OFT today recommended that the Pharmaceutical Price Regulation Scheme ( PPRS ) should be reformed, to deliver better value for money from NHS drug spend and to focus business investment on drugs that have the greatest benefits for patients.
A new study led by researchers at the McGill University Health Centre (MUHC) has identified four genes that increase the risk of developing type 2 diabetes.